ALT5 Sigma (ALTS) Stock Overview
Provides blockchain-powered technologies worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ALTS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ALT5 Sigma Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.13 |
| 52 Week High | US$10.95 |
| 52 Week Low | US$1.29 |
| Beta | 2.32 |
| 1 Month Change | -12.67% |
| 3 Month Change | 82.70% |
| 1 Year Change | 279.91% |
| 3 Year Change | 211.49% |
| 5 Year Change | 151.70% |
| Change since IPO | -95.61% |
Recent News & Updates
Recent updates
Calculating The Fair Value Of ALT5 Sigma Corporation (NASDAQ:ALTS)
Jun 30
Would ALT5 Sigma (NASDAQ:ALTS) Be Better Off With Less Debt?
Apr 05Here's Why ALT5 Sigma (NASDAQ:ALTS) Can Afford Some Debt
Feb 28Does ALT5 Sigma (NASDAQ:ALTS) Have A Healthy Balance Sheet?
Nov 15JanOne Inc.'s (NASDAQ:JAN) Share Price Boosted 153% But Its Business Prospects Need A Lift Too
Mar 31JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry
Feb 14Shareholders May Be A Bit More Conservative With JanOne Inc.'s (NASDAQ:JAN) CEO Compensation For Now
Oct 03JanOne to acquire Soin Therapeutics
Sep 16Does JanOne (NASDAQ:JAN) Have A Healthy Balance Sheet?
Aug 17Health Check: How Prudently Does JanOne (NASDAQ:JAN) Use Debt?
Mar 21Is JanOne (NASDAQ:JAN) Using Debt In A Risky Way?
Nov 19Shareholder Returns
| ALTS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -11.0% | 0.5% | 3.4% |
| 1Y | 279.9% | -11.2% | 13.7% |
Return vs Industry: ALTS exceeded the US Pharmaceuticals industry which returned -11.2% over the past year.
Return vs Market: ALTS exceeded the US Market which returned 13.7% over the past year.
Price Volatility
| ALTS volatility | |
|---|---|
| ALTS Average Weekly Movement | 16.5% |
| Pharmaceuticals Industry Average Movement | 11.6% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: ALTS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ALTS's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 10 | Peter Tassiopoulos | alt5sigma.com |
ALT5 Sigma Corporation, together with its subsidiaries, provides blockchain-powered technologies worldwide. It operates through Fintech and Biotechnology segments. The company engages in the tokenization, trading, clearing settlement, payment, and safe keeping of digital assets.
ALT5 Sigma Corporation Fundamentals Summary
| ALTS fundamental statistics | |
|---|---|
| Market cap | US$141.91m |
| Earnings (TTM) | -US$6.96m |
| Revenue (TTM) | US$18.05m |
Is ALTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALTS income statement (TTM) | |
|---|---|
| Revenue | US$18.05m |
| Cost of Revenue | US$9.16m |
| Gross Profit | US$8.89m |
| Other Expenses | US$15.85m |
| Earnings | -US$6.96m |
Last Reported Earnings
Mar 29, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 49.24% |
| Net Profit Margin | -38.58% |
| Debt/Equity Ratio | 48.5% |
How did ALTS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/30 21:46 |
| End of Day Share Price | 2025/06/27 00:00 |
| Earnings | 2025/03/29 |
| Annual Earnings | 2024/12/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ALT5 Sigma Corporation is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ryan McGaver | Capstone Investments |
| Gregory Mesniaeff | Kingswood Capital |